Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
about
Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapyThymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy.Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resectionA polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracilSynergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumorsPhase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathwayPrognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patientsColorectal cancer staging and adjuvant chemotherapy.Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.Future potential of thymidylate synthase inhibitors in cancer therapy.Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivoDetection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.Pharmacogenomics: road to anticancer therapeutics nirvana?Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.Antimetabolite Treatment for Pancreatic Cancer.Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinomaGenetic factors influencing pyrimidine-antagonist chemotherapy.Tailor-made chemotherapy for non-small cell lung cancer patients.Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancerCombined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFTERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinomaA dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
P2860
Q24795468-904C4051-3AF8-4464-ABDA-C46F0C7D3EC2Q27851727-65AB675D-7210-4783-8FA3-DA8694656C59Q28303251-3CE81647-FA71-4158-B4B4-8D0918CF05DDQ28346756-050CF4C2-603F-40DA-B60B-EB062753EED0Q28352447-37F0110A-64C5-4617-AE36-0791F93F296DQ28533752-540739E1-498F-4F04-A054-623A4E589280Q30834530-1A44D266-FAE7-49DA-A24C-CDD130AD3562Q31098180-6F2516CC-FFA4-49A7-A2B1-E58C07A15244Q33317139-FC6BA755-8341-40E1-9DF7-7C319D2ADBA1Q33327609-68A52E3E-D666-401E-922D-B1400A8E4580Q33337970-919A666F-74C4-4F2D-B4C2-E583C8073798Q33372119-74E7488E-BA82-4E23-BD02-BA66689605ADQ33884698-D1A6D78A-B843-435F-97D0-B5CF2D27D9A1Q33944623-A425DC7F-34DF-4BF5-8A04-A9F1D03D2E99Q34182099-4190472B-C10D-4125-A8A4-AEB213EC05C3Q34620545-A848A32D-2E1D-459E-BE59-350E641E10BCQ34743494-2B51541B-0DAD-4C63-9B02-75CB8301BDE0Q34847802-125AAAC9-552E-4FE6-A914-34433BFA0F12Q34894800-C28B478D-FF16-4092-9469-59138BF87A61Q34989932-8B54E299-1040-4E28-9518-6D602CDE18E2Q35000906-89ACBD4C-DAEE-4153-ABAA-F97D8F197A70Q35011904-56C3C8D0-0367-480E-B4D5-15BA4D5905A4Q35048000-E73C611F-5795-44A3-84A8-0654BABBDD3DQ35083755-98A85C8B-FB63-4209-AE41-6C26AB7D54D3Q35551155-5153399B-EC36-494E-ACB5-534BF9F0227DQ35615776-E3EAC46A-1A61-4582-A1FE-EDC82388FCCCQ35826334-E27ABBB7-A4A8-4717-93BF-914CD0CE6491Q35875892-785A3A60-8F1F-4B8B-94C6-EBEEA2CE8BC2Q35878616-D4131033-F5F1-467A-A3DD-CDAF41C1075AQ36097126-C3EC8D72-FDAE-4C61-851A-8656B80A470AQ36205831-9535A205-450E-4666-B09E-E0CCE314E015Q36430761-02BF0304-26D7-4B30-BA14-411F1AEE8D53Q36609741-C78B7049-C130-4769-8CE1-93F9E5C2098AQ36610915-B1C51AD9-9C8C-455A-9121-12A04E2D0719Q36612324-12CB86EB-6B3B-49EB-8CDA-71CE28889F1EQ36615632-BD005FEA-6174-46A0-BAC0-E73683775D4DQ36616168-0AD3317C-A05F-421B-A0EF-EC41DB890613Q36619868-A5EDB597-9B46-4D17-AC47-2C4FCB10D4EAQ36620979-48C9A780-BE9D-4713-9E1B-BF255FE2155CQ36621545-7D140CD2-EC1B-4FA6-894C-04275B3C693D
P2860
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Thymidylate synthase mRNA leve ...... response and overall survival.
@en
Thymidylate synthase mRNA leve ...... response and overall survival.
@nl
type
label
Thymidylate synthase mRNA leve ...... response and overall survival.
@en
Thymidylate synthase mRNA leve ...... response and overall survival.
@nl
prefLabel
Thymidylate synthase mRNA leve ...... response and overall survival.
@en
Thymidylate synthase mRNA leve ...... response and overall survival.
@nl
P2093
P1476
Thymidylate synthase mRNA leve ...... response and overall survival.
@en
P2093
C G Leichman
H Silberman
K D Danenberg
L Leichman
P304
P356
10.1200/JCO.1996.14.1.176
P407
P577
1996-01-01T00:00:00Z